A rapid rituximab infusion pilot study
Clinical Previous    

A rapid rituximab infusion pilot study

Paula Statham Nurse manager, Ambulatory cancer care unit, employed at University College London Hospitals NHS Foundation Trust, London
Catherine Demosthenous Nurse manager, Ambulatory cancer care unit, employed at University College London Hospitals NHS Foundation Trust, London
Simon Cheesman Haematology pharmacist, Employed at University College London Hospitals NHS Foundation Trust, London
Helen Keane Day care nurse manager, Employed at University College London Hospitals NHS Foundation Trust, London

Given the extended license for rituximab (MabThera) and the anticipated increase in demand for its use in chemotherapy units, a pilot study investigating its rapid infusion was carried out in the haematology unit of a London cancer centre. The study revealed that 90 minute rapid rituximab infusions may be administered safely during second and subsequent treatments to eligible patients. This finding may have significant implications for day care resources, appointment scheduling and patient satisfaction, and therefore warrants further investigation

Cancer Nursing Practice. 5, 6,35-38. doi: 10.7748/cnp2006.07.5.6.35.c7580

You need a subscription to read the full article